



Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

AUG 28 1997

Mr. Bruce R. Williams
Executive Vice President
Bionostics, Inc.
2 Craig Road
Acton, Massachusetts 01720-5405

Re: K972868
Trade Name: Blood Gas/Electrolyte/Glucose, Lactate, BUN, and
Creatinine Control
Regulatory Class: I
Product Code: JJY
Dated: July 31, 1997
Received: August 4, 1997

Dear Mr. Williams:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal Laws or Regulations.


Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>"

Sincerely yours,



Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical
Laboratory Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

BIONOSTICS

510(k) Number: Not yet assigned

Device Name: Blood Gas, Electrolyte, Glucose, Lactate, BUN and Creatinine Quality Control Product

Date of Submission: 31 July 1997

INDICATIONS FOR USE:

A. INTENDED USE

This material is intended for use to monitor the measurements of:


- a. pH and pCO₂ and pO₂ in blood gas analyzers,
- b. Na, K, Cl, Li, Ca⁺⁺, and Mg⁺⁺ in electrolyte analyzers, and;
- c. glucose, lactate, BUN and creatinine in analyzers which measure these metabolites.

The Control is provided at three clinically significant levels to make possible verification of instrument performance at different points for each analyte.

This product is for In Vitro Diagnostic Use only.

B. Determination of acid-base status, and the concentrations of oxygen, carbon dioxide, electrolytes and certain critical metabolites in arterial blood is an important adjust to patient monitoring for a variety of clinical conditions.

Since therapeutic regiments are often determined by the results obtained on patient samples, the instruments used to perform these measurements must meet stringent requirements for accuracy and precision. The use of this quality control material is to confirm the performance of instruments which measure critical blood analytes (i.e. electrolytes and critical metabolites) and blood gases and pH.


 Bruce R. Williams August 8, 1997


 (Division Sign-Off)
 Division of Clinical Laboratory Devices
 510(k) Number K972868